CKD-MBD: impact on management of kidney disease.
CKD-MBD: impact on management of kidney disease.
复制标题
DOI：
10.1007/s10157-007-0492-5
复制
发表时间：
2007-12-01
影响因子：
2.3
通讯作者：
Akizawa, Tadao
中科院分区：
文献类型：
--
作者：
Ogata, Hiroaki;Koiwa, Fumihiko;Akizawa, Tadao
慢性肾脏病（CKD）引起各种骨矿物质紊乱，最近被命名为CKD矿物质和骨紊乱（CKD-MBD）。CKD-MBD与终末期肾病（ESKD）人群中极高的心血管疾病（CVD）发病率和死亡率相关。因此，CKD-MBD的最佳管理将导致尿毒症患者心血管发病率和死亡率的降低。此外，已经表明CKD-MBD的治疗对CKD的进展具有一些有利的影响。最近，新的治疗药物，包括活性维生素D类似物，不含钙的磷结合剂，西那卡塞，已成为临床可用。在这篇文章中，我们审查新的治疗策略，慢性肾脏病-MBD。
Chronic kidney disease (CKD) causes various bone mineral disorders, which have recently been named CKD mineral and bone disorder (CKD-MBD). CKD-MBD is associated with extremely high cardiovascular disease (CVD) morbidity and mortality in the endstage kidney disease (ESKD) population. Thus, optimal management of CKD-MBD would lead to a reduction in cardiovascular morbidity and mortality in uremic patients. In addition, it has been suggested that the treatment of CKD-MBD has some favorable effects on the progression of CKD. Recently, novel therapeutic agents, including active vitamin D analogues, noncalcium-containing phosphate binders, and cinacalcet, have become clinically available. In this article, we review novel therapeutic strategies for CKD-MBD.